Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K current report with the SEC on March 18, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Full year 2025 financial results announced, details in press release titled “4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones”.
4D Molecular Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full year 2025 financial results announced, details in press release titled “4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones”
- Press release furnished as Exhibit, key financial and operational updates available there
- Signals transparency on 2025 performance, guiding investor expectations for upcoming milestones
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 4D Molecular Therapeutics, Inc. 8-K filings
Get the next FDMT 8-K as it lands
Follow FDMT for push alerts, or ask the research agent what this filing means.